Colorectal Cancer

New Protocol: Tucatinib and Trastuzumab for Metastatic Colorectal Cancer

2023-03-15

  • Study

    Phase II, open-label, multicenter study
    Pretreated, HER2-positive, RAS wild-type, unresectable or metastatic colorectal cancer
    Tucatinib + Trastuzumab q21 (n=117)

  • Efficacy

    ORR: 38% [28-49]
    DoR: 12.4 mos [8.5-20.5]


  • Safety

    Any grade AEs: Diarrhea (33%), fatigue(20%), abdominal pain (20%)
    Grade 3 AEs: ALT/AST increase (6.7% of both)



    • Article no yet published

    Tucatinib Plus Trastuzumab Active in Metastatic Colorectal Cancer

    http://www.ncbi.nlm.nih.gov/pubmed/0

    Reviewed by Elvin Chalabiyev, MD on Mar 15, 2023